Navigation Links
Pivotal MIRCERA(R) Study First to Convert Dialysis Patients From Frequent Dosing Directly to Once Every Two Weeks or Once Every Four Weeks
Date:10/19/2007

- MAXIMA findings in The Lancet affirm the maintenance of hemoglobin levels

with less frequent dosing -

NUTLEY, N.J., Oct. 19 /PRNewswire/ -- A pivotal study published today in The Lancet has shown that dialysis patients were effectively switched from frequently-dosed anemia drugs to an innovative investigational anemia treatment, MIRCERA(R), administered up to once every four weeks(1)

The MAXIMA study is the first randomized, comparative study to investigate the direct conversion of dialysis patients with chronic kidney disease from treatment with erythropoiesis-stimulating agents (ESA) given one to three times a week to IV MIRCERA administered once every two weeks or once every four weeks. The results demonstrated that MIRCERA maintained hemoglobin (Hb) concentrations within the target range as effectively as ESAs epoetin alfa or beta, which are typically given three times a week.

"Our findings demonstrate that MIRCERA was administered up to once every four weeks in hemodialysis patients without sacrificing hemoglobin stability," said Nathan Levin, M.D., Medical and Research Director, Renal Research Institute, New York, New York, and the lead author of the publication. "We note in The Lancet that these results should be generalizable to the maintenance hemodialysis population and that we believe this drug should be an option to epoetin for simplified anemia management."

About the MAXIMA Study

The MAXIMA study randomized 673 adult patients with stable chronic renal anemia on dialysis therapy and IV maintenance epoetin at 91 centers in eight countries. Most patients were from North America (U.S. - 68 percent; Canada - 11 percent) and Europe (21 percent). The study compared two administration intervals of IV MIRCERA (once every two weeks or once every four weeks) with continued IV epoetin treatment (one to three-times a week) in patients with chronic renal anemia. After a run-in period, patients were randomly assigned to either of the MIRCERA arms or to continue epoetin alfa or beta at their current dose and administration interval. Patients randomized to MIRCERA received a starting dose based on the previous weekly dose of epoetin.

In contrast to previous studies in which dialysis patients were converted from IV epoetin using sequential increases in dosing intervals, most patients in MAXIMA were converted directly from a predominantly three-times-a-week regimen of epoetin (87 percent of patients) to IV MIRCERA administered once every two weeks or once every four weeks.

MAXIMA Study Findings

The MAXIMA results showed:

-- Minute changes in Hb levels throughout the duration of the study (mean

changes from the baseline to the evaluation periods were -0.71, -0.25,

and -0.75 g/L in the MIRCERA once every two weeks; MIRCERA once every

four weeks and epoetin groups, respectively), illustrating that the

primary efficacy parameter (mean change in Hb level between baseline

and evaluation periods) was met.

-- For the secondary analysis, the proportion of patients maintaining a

mean Hb within plus or minus 10 g/L of baseline was 68 percent, 68

percent, and 67 percent in the MIRCERA once every two weeks and MIRCERA

once every four weeks and epoetin groups, respectively.

-- The most common serious adverse events in the three groups were sepsis,

pneumonia and arteriograft thrombosis. A similar incidence of adverse

events occurred across all treatment arms with the most frequent

adverse events mild to moderate and had a distribution typical for this

patient population.

About MIRCERA

The clinical program for MIRCERA consisted of 10 global studies involving more than 2,700 patients from 29 countries. The Phase III program for MIRCERA included two correction studies and four maintenance studies exploring intravenous (IV) and subcutaneous (SC) MIRCERA at extended administration intervals. MIRCERA has a longer half-life than any commercially available erythropoiesis-stimulating agent (ESA). In clinical trials MIRCERA corrected anemia in chronic kidney disease (CKD) patients with dosing once every two weeks and maintained hemoglobin levels in CKD patients with dosing intervals up to once monthly. In the U.S., the FDA is completing its review and MIRCERA is anticipated to be approved mid-November.

Safety Information

MIRCERA has a demonstrated safety profile comparable to other erythropoietic agents. The most commonly reported adverse events in the MIRCERA Phase II/III clinical program were hypertension, nasopharyngitis, diarrhea, headache, and upper respiratory tract infection.

Erythropoietic therapies increase the risk of death and serious cardiovascular and thromboembolic events when administered to a hemoglobin of greater than 12 g/dL. A rate of Hb rise of >1 g/dL over 2 weeks may also contribute to these risks.

Erythropoiesis stimulating agents, when administered to target a hemoglobin of greater than 12 g/dL, have shortened the time to tumor progression, shortened survival and increased the risk of death in cancer patients.

Pure Red Cell Aplasia (PRCA) has been observed in patients treated with erythropoietin therapy. However, PRCA has not been observed with MIRCERA in clinical trials to date.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2007 Roche was named Top Company of the Year by Med Ad News and one of the Top 20 Employers (Science magazine). In 2006, Roche was ranked the No. 1 Company to Sell For (Selling Power), and one of AARP's Top Companies for Older Workers, and in 2005, Roche was named one of Fortune magazine's Best Companies to Work For in America. For additional information about the U.S. pharmaceuticals business, visit our websites: http://www.rocheusa.com or http://www.roche.us.

All trademarks used or mentioned in this release are protected by law.

(1) N. W Levin, S. Fishbane, F. Valdes Canedo, S. Zeig, G. M Nassar, J. E

Moran, G. Villa, U. Beyer, D. Oguey, on behalf of the MAXIMA study

investigators. "Intravenous methoxy polyethylene glycol-epoetin beta

for haemoglobin control in patients with chronic kidney disease who

are on dialysis: a randomised non-inferiority trial (MAXIMA)." The

Lancet, Vol 370, Pages 1415-1421. October 20, 2007


'/>"/>
SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... , May 30, 2016 ... reach USD 7.3 billion by 2024, according to ... The increasing natality rate, the growing malnutrition coupled ... cancer and gastro-intestinal tract diseases are expected to ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ...
(Date:5/30/2016)... LifeScienceIndustryResearch.com adds "Ulcerative Colitis ... with comprehensive information on the therapeutic development for ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Ulcerative Colitis ...
(Date:5/27/2016)... LabStyle Innovations Corp . ( ... today announced that the Company,s Chief Financial Officer, Zvi ... held June 1-2 in New York, NY ... in Los Angeles, CA. ... operational milestones, including the U.S. FDA Clearance and commercial launch ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... ... firm and statement solutions provider, for the tenth consecutive year as a ... issue of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing ...
(Date:5/31/2016)... ... May 31, 2016 , ... CURE ... patients with cancer, has added Cancer and Careers to its ... timely content on continuing successful careers while fighting cancer. , As partners, both ...
(Date:5/30/2016)... ... ... As the CDC relaxes its stance on traditional No-Nit policies, parents wonder what ... free. , According to a May 26 article from news source KHON2 ... despite the fact that they may be harboring an infestation. Previous No-Nit policies stated ...
(Date:5/30/2016)... ... May 30, 2016 , ... Zane Benefits, the leader ... an original infographic, " Health Benefits Reimbursement Compliance Timeline ." , The ... complies with various federal regulations and reforms. , Navigating the new health reforms ...
(Date:5/30/2016)... ... May 30, 2016 , ... Another ER facility operated ... Plano, located at 3960 Legacy Drive, Plano, TX and is open 24 hours daily. ... Commerce followed by a medical open house. The Jasper High School band entertained attendees ...
Breaking Medicine News(10 mins):